Tamtam Try Tamtam free
Cencora logo

Cencora account plan

pharmaceutical distribution and services

At a glance

Cencora is a global pharmaceutical sourcing and distribution company with $321.3 billion of FY2025 revenue and more than 51,000 employees.

Cencora, formerly AmerisourceBergen and based in Conshohocken, PA, distributes brand-name, specialty and generic pharmaceuticals to hospitals, health systems, pharmacies, physician practices and veterinarians, and sells logistics, consulting and data services to drug manufacturers. It operates in over 50 countries, with about 9% of revenue from international operations. In FY2025 (year to September 30, 2025) revenue was $321.3 billion, operating income $2.63 billion and net income attributable to Cencora $1,554 million. It had more than 51,000 employees, about 41% in the U.S., and describes itself as ranked #10 on the Fortune 500.

Business units

Strategic priorities

Specialty pharmaceutical platform
The CEO calls Cencora's "differentiated specialty pharmaceutical platform" its first growth priority, built on specialty distribution, the RCA and OneOncology management services organizations, World Courier and health-system services. MSO expansion is limited to tuck-ins in oncology and retina.
Digital transformation of the supply chain
Teams use AI to anticipate product needs in demand forecasting, and the company launched AI-supported customer support tools. U.S. distribution centers run on a single ERP system.
Portfolio focus
Non-core businesses are being divested: U.S. hub consulting sold in April 2026, MWI Animal Health to merge with Covetrus, and strategic alternatives explored for Profarma and parts of PharmaLex.
Talent and leadership change
Eva Boratto joined as EVP and CFO and Samantha Hammock as EVP and CHRO in 2026, replacing Jim Cleary and Silvana Battaglia.
Long-term growth framework
Management reaffirmed 7% to 10% organic operating income growth, another 3% to 4% from capital deployment and 10% to 14% EPS growth.

Latest results

In Q3 FY2026 (quarter to June 30, 2026) revenue was $84.8 billion, up 5.1%, and adjusted diluted EPS rose 12.0% to $4.48. Adjusted operating income grew 17.0% to $1.2 billion, and the adjusted gross margin rose 61 basis points to 4.16%, lifted by OneOncology. U.S. growth came from specialty sales and GLP-1s (+$2.3 billion), offset by manufacturer list price cuts, a $2.4 billion revenue headwind, the loss of an oncology customer and lower sales to the large mail order customer. Fiscal 2026 adjusted EPS guidance was raised to $17.75-$17.95, with revenue growth of 4% to 6% and adjusted free cash flow of about $3.0 billion.

Investments and deals

OneOncology acquisition
On February 2, 2026 Cencora acquired the majority of OneOncology it did not own, for total fair value consideration of $7,387.1 million, including $4,648.7 million in cash, financed with $3.0 billion of senior notes and $1.5 billion of term loans.
Retina Consultants of America
An 85% interest in RCA was acquired on January 2, 2025 for $4,042.0 million in cash; RCA contributed $2.1 billion of revenue in FY2025.
Capital expenditure
Capex was $668.0 million in FY2025 for distribution network expansion and technology, and about $900 million is expected in FY2026.
Share repurchases and dividend
$1 billion of shares were repurchased in Q3 FY2026, a new $2.0 billion programme was authorised in May 2026, and the quarterly dividend is $0.60 per share.

Challenges and risks

Drug-pricing policy
Risks include IRA negotiated prices, Executive Order 14297 on most-favored-nation pricing, the CMS bona fide service fee rule, 340B rebate models and WAC price reductions.
Customer concentration
The top 10 customers were about 66% of FY2025 revenue; Walgreens and Boots about 25% and Evernorth Health Services about 13%. WBA was acquired by Sycamore Partners on August 28, 2025, and the new owners may seek changes to the relationship.
Biosimilar conversions and slower GLP-1 growth
Faster brand-to-biosimilar conversions at the large mail order customer and slower GLP-1 growth led Cencora to cut FY2026 revenue growth guidance to 4% to 6% from 7% to 9%.
Opioid liabilities
The accrued opioid liability was $4.3 billion at September 30, 2025, payable over the next 13 years.
Cybersecurity and regulation
A fiscal 2024 cybersecurity event led to data exfiltration, and the Drug Supply Chain Security Act's traceability requirements "will continue to increase the cost of our operations".

What leadership says

“Our investments in specialty, digital transformation and talent are strengthening our ability to support our customers across the healthcare ecosystem while positioning Cencora for sustainable long-term growth.”

Robert P. Mauch, President and CEO · Fiscal 2026 third quarter results press release, August 5, 2026

“We serve as the backbone of the pharmaceutical supply chain”

Robert P. Mauch, President and CEO · Q2 fiscal 2026 earnings call, May 6, 2026

“we have to demonstrate our value all the time”

Robert P. Mauch, President and CEO · Q2 fiscal 2026 earnings call, May 6, 2026

“Biosimilars are good. Biosimilars are good for patients.”

Robert P. Mauch, President and CEO · Q3 fiscal 2026 earnings call, August 5, 2026

Where a supplier can help

AI for supply chain and customer support
Digital transformation is a named growth priority, with AI already used for demand forecasting and customer support; suppliers of forecasting, automation and support tooling fit it.
Warehouse and distribution technology
About $900 million of FY2026 capex goes to distribution network expansion and technology, alongside continued warehouse automation.
Services for oncology and retina practices
The MSO value plan moves from integrating OneOncology and RCA to shared capabilities such as clinical trials, then new analytics services, which creates needs for clinical-trial, practice-management and analytics vendors.
Traceability, compliance and security
Drug Supply Chain Security Act traceability costs and the cybersecurity risk after the fiscal 2024 data exfiltration point to compliance, track-and-trace and security offerings.
Divestiture and integration support
Portfolio focus (the MWI-Covetrus merger, the PharmaLex and Profarma reviews) and acquisition integration call for advisory, separation and integration services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Cencora?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Cencora

What does Cencora do?

Cencora is a pharmaceutical sourcing and distribution company. It supplies drugs to hospitals, pharmacies, physician practices and veterinarians, and sells logistics, consulting and commercialization services to drug manufacturers, in the U.S. and over 50 countries.

What is Cencora's revenue?

Revenue was $321.3 billion in FY2025 (year to September 30, 2025), up 9.3%, with operating income of $2.63 billion. For FY2026 the company guides to 4% to 6% revenue growth.

How many employees does Cencora have?

Cencora had more than 51,000 employees at September 30, 2025, about 41% of them in the U.S.

What is Cencora's strategy?

Its three growth priorities are a specialty pharmaceutical platform (including the RCA and OneOncology practice networks), digital transformation of the supply chain, and talent, while divesting non-core businesses such as MWI Animal Health.

Who leads Cencora?

Robert P. Mauch has been President and CEO since October 2024. Eva Boratto is EVP and CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)